Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by lonc17on Nov 17, 2023 1:56pm
126 Views
Post# 35741556

RE:RE:RE:RE:RE:RE:RE:RE:Institutional investor

RE:RE:RE:RE:RE:RE:RE:RE:Institutional investor
Canadafan,

It is very unlikely that you will see any record of Anson holding shares in ONC subsequent to their latest reporting. You have to be very naive to believe that Anson has acutally invested about 15 million (CDN) in a lousy little biotech like ONC.

In the good old days, a small cap biotech would raise capital in an honest fashion though an offering, inclusive of a prospectus on each occasion, usually once every two years or so. There would be a consortium of instituions who would pick up the offereing at a slight discount to market and then peddle them off to their clients. It always hurt the share price in the short term but it was an expected course of business.

Then someone invented ATM's.

With an ATM, ONC would issue a long standing prospectus and then invite someone like Canacord or (even worse) Lincoln Park Capital to sell a prescribed number of shares into the market every month. Essentially, LPC would be selling shares short every month and then ONC would issue shares from their treasury (at a discount) to cover LPC. It was a steady stream of cash for a lousy little biotech like ONC and it allowed them to continue to pay very generous salaries to management for a number of years.

Then along comes Anson. (The following is specluative and my opinion only).

IMO, Anson saw an opportunity to short millions of shares of ONC during the months of June and July this year. I believe this likely invloved a bit of wash trading on the busiest days to excite naive investors. In August, they want to cover their short position and they approach ONC with a tidy little sum of money. ONC jumps at it and issues shares from treasury at a heavily discounted price. The reason Anson shows on record as owning these shares (for now) may be due to shorting in different acounts. By the next accounting period Anson will have disappeared completely from any investment in ONC.

Of course, Anson could only have success with this due to MC's epic failure to do any due diligence on their offer.

<< Previous
Bullboard Posts
Next >>